Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated.
Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia. a critical review of the literature / Busetto, G.M., Del Giudice, F., D'Agostino, D., Romagnoli, D., Minervini, A., Rocco, B., Antonelli, A., Celia, A., Schiavina, R., Cindolo, L., Chung, B.I., Kim, J.H., Maggi, M., Sciarra, A., De Berardinis, E., Porreca, A.. - In: ARCHIVIO ITALIANO DI UROLOGIA ANDROLOGIA. - ISSN 1124-3562. - 91:4(2019), pp. 205-211. [10.4081/aiua.2019.4.205]
Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia. a critical review of the literature
Busetto, Gian Maria
;Del Giudice, Francesco;Minervini, Andrea;Rocco, Bernardo;Antonelli, Alessandro;Celia, Antonio;Maggi, Martina;Sciarra, Alessandro;De Berardinis, Ettore;
2019
Abstract
Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On the other hand, 5-ARI monotherapy and in particular Finasteride alone is currently getting focus of attention especially due to lack of systematic reviews investigating efficacy outcomes and/or adverse events associated.| File | Dimensione | Formato | |
|---|---|---|---|
|
Busetto_Efficacy-safety-finasteride_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
881.66 kB
Formato
Adobe PDF
|
881.66 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
